ATLANTA—High-intensity focused ultrasound (HIFU) provides shows promise as a salvage treatment option men with recurrent prostate cancer (PCa) following external beam radiotherapy (EBRT), data presented at the American Urological Association annual meeting suggest.
French researchers analyzed data from 982 men (average age 68.8 years) who underwent salvage HIFU treatment for recurrent PCa following EBRT (411 who first received hormone treatment and 571 who did not). The median pre-HIFU PSA level was 14.6 ng/mL and the median Gleason sum was 7. Patients were followed for two years after HIFU treatment.
The median PSA nadir was 0.2 ng/mL, which was reached 13.4 weeks after salvage HIFU. The salvage treatment rate after HIFU was 35.7%, but was higher for those who had received hormone treatment than for those who did not (45.7% vs. 28.5%).
The unstratified actuarial biochemical disease-free survival (BDFS) rates at four, five, and six years were 57%, 51%, and 46%, respectively.
The investigators concluded that HIFU salvage treatment achieved good overall cancer control.